MSPs get to benefit from every important IT trend that comes along, whether that's cybersecurity or data and AI,' said FFL's ...

Abacus Group and Medicus IT, two leading providers of IT managed services with deep subject matter expertise in the highly ...

FFL Partners ("FFL"), a private equity firm focused on growth investments in tech-enabled business services and healthcare companies, today announced the completion of the merger of FFL portfolio ...

Medicus Pharma offers high-risk, high-reward potential, with its novel SkinJect patch for basal cell carcinoma and Antev ...

Pro Medicus’ strategy revolves around renewing existing contracts and winning new clients for its main product, Visage 7, while increasing its price point. The company won six out of six major ...

About Medicus Pharma Ltd: Medicus Pharma Ltd. (NASDAQ: MDCX) is a biotech/life sciences company focused on accelerating the clinical development programs of novel and disruptive therapeutics assets.

Medicus to acquire Antev and expand into urology with Teverelix while reporting positive data in its Phase 2 skin cancer trial for D-MNA.

Whenever the healthcare imaging software group signs a new customer contract, fund managers hide under their desks. This latest one really hurts.

The Pro Medicus Ltd (ASX: PME) share price is racing higher today. Here’s why investors are piling into the ASX 200 ...

Pro Medicus (ASX: PME) won a contract with UCHealth of at least $170 million over 10 years, marking its second-largest ...

Subject to the closing conditions noted in the Definitive Agreement, Medicus will acquire all issued and outstanding Antev Shares, on a fully diluted basis, in exchange for 2,666,600 (or ...